Glasdegib is primarily used in the treatment of acute myeloid leukemia (AML), particularly in adult patients who are 75 years or older or those who have comorbidities that make intensive chemotherapy unsuitable. It is often prescribed in combination with low-dose cytarabine (LDAC) to enhance its efficacy. The drug works by inhibiting the Hedgehog signaling pathway, which is involved in the growth and survival of cancer cells. This targeted approach helps to slow the progression of the disease and improve overall survival rates. Glasdegib is administered orally, making it a convenient option for patients who require long-term treatment. Its use is carefully monitored due to potential side effects, including muscle spasms, fatigue, and changes in blood counts.